Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

Background. We are developing cancer immunotherapy based on the use of autologous tumor tissue that has been rendered replication-incompetent but maintains phenotype and metabolic activity post-preparation. Aim. The aim of this study was to evaluate safety and tolerance to injection of the inactivat...

Full description

Bibliographic Details
Main Authors:	Raymond P. Goodrich, Jon Weston, Lindsay Hartson, Lynn Griffin, Amanda Guth
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2020/7142375

Similar Items

Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.
by: Izabela Ragan, et al.
Published: (2020-01-01)

Cellular Immunotherapy of Canine Cancer
by: Selamawit Addissie, et al.
Published: (2018-12-01)

Immunotherapy and imaging diagnosis of canine cancers
by: Tien-Fu Chuang, et al.
Published: (2011)

Analgesic Effect of Meloxicam in Canine Acute Dermatitis – a Pilot Study
by: Frendin J, et al.
Published: (2002-12-01)

Studies on Diagnosis and Allergen-Specific Immunotherapy of Canine Atopy
by: Ming-Chuan Chu, et al.
Published: (2011)

Development of targeted immunotherapy for canine mast cell tumours
by: Elders, Richard Christopher
Published: (2010)

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
by: William C. Kisseberth, et al.
Published: (2021-06-01)

Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target
by: Alicia A. Gingrich, et al.
Published: (2021-09-01)

IMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL ENRICHMENT IN A CANINE MODEL OF AGING
by: Davis, Paulina R
Published: (2014)

Canine anti-endotoxin immunotherapy in cranial mesenteric arterial occlusion shock and canine parvovirus disease endotoxaemia.
by: Wessels, Brian C.
Published: (2011)

Sublingual Immunotherapy in Human and Canine Atopic Dermatitis: A Mini Review
by: Ibrahim Ozmen, et al.
Published: (2014-10-01)

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.
by: Sharon M Barth, et al.
Published: (2016-01-01)

Safety of Hyaluronan 35 in Healthy Human Subjects: A Pilot Study
by: Annette Bellar, et al.
Published: (2019-05-01)

Canine-Assisted Interventions in Hospitals: Best Practices for Maximizing Human and Canine Safety
by: Sandra B. Barker, et al.
Published: (2021-03-01)

Prognostic Factors in Canine Acute Intervertebral Disc Disease
by: Natasha J. Olby, et al.
Published: (2020-11-01)

Immunotherapies for Acute Myeloid Leukemia
Published: (2020)

139 Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development
by: Peter Moore, et al.
Published: (2020-11-01)

Dose dependence of efficacy but not of safety in sublingual immunotherapy
by: F. Frati, et al.
Published: (2016-02-01)

Dose dependence of efficacy and safety of subcutaneous immunotherapy
by: C. Incorvaia, et al.
Published: (2016-02-01)

Emerging Immunotherapy for Acute Myeloid Leukemia
by: Rikako Tabata, et al.
Published: (2021-02-01)

Immunotherapy for acute-on-chronic liver failure
by: HAN Ying, et al.
Published: (2017-09-01)

The Value of Immunotherapy in Acute Myeloblastic Leukaemia
by: Freeman, C. B.
Published: (1975)

Oral Mucosal Immunotherapy for Allergic Rhinitis: A Pilot Study
by: William R. Reisacher M.D., et al.
Published: (2016-03-01)

Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy)
by: Richard Stock, et al.
Published: (2021-01-01)

Transsphenoidal Surgery in Canines: Safety, Efficacy and Patient Selection
by: Hara Y
Published: (2020-01-01)

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up
by: Sara Saellstrom, et al.
Published: (2021-07-01)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
by: Michael M Boyiadzis, et al.
Published: (2020-07-01)

The Safety of Immunotherapy in Patients with Allergic Asthma and Allergic Rhinitis
by: G. Ilonidis, et al.
Published: (2005-01-01)

Allergen immunotherapy: routes, safety,efficacy, and mode of action
by: Hochfelder JL, et al.
Published: (2013-07-01)

SAFETY OF VENOMENHAL® VENOM IN MAINTENANCE HYMENOPTERA VENOM IMMUNOTHERAPY
by: Mitja Košnik, et al.
Published: (2001-10-01)

A canine model of normovolaemic acute anaemia
by: T.C. Spotswood, et al.
Published: (2005-09-01)

Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia
by: David Pesántez, et al.
Published: (2017-08-01)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
by: Jochen Greiner
Published: (2019-11-01)

Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia
by: Ghazala Naz Khan, et al.
Published: (2019-01-01)

Recent developments in immunotherapy of acute myeloid leukemia
by: Felix S. Lichtenegger, et al.
Published: (2017-07-01)

Current status of immunotherapy in acute myeloid leukemia
by: Li Wenrui
Published: (2021-01-01)

Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.
by: Josie Haydée Lima Ferreira, et al.
Published: (2014-03-01)

Characterisation and In Vivo Safety of Canine Adipose-Derived Stem Cells
by: Bērziņš Uldis, et al.
Published: (2018-06-01)

The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study
by: Jana Dluha, et al.
Published: (2016-12-01)

Safety of a Bioactive Polyphenol Dietary Supplement in Pediatric Subjects with Acute Diarrhoea
by: Shafiqul A. Sarker, et al.
Published: (2015-01-01)